Researchers observed that only 8.3% of 24 children or adolescents with peanut allergy passed a double-blind placebo-controlled food challenge with at least 444 mg of peanut protein after receiving ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

The following is a summary of “Longitudinal integrated proteomic and metabolomic skin changes in atopic dermatitis patients ...

Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...

In a clinical guideline issued by the American College of Gastroenterology and published in the January issue of the American ...

Patients with atopic dermatitis using dupilumab vs conventional drugs had less risk for psychiatric and sleep disorders.

1 Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy 2 Azienda Ospedaliero-Universitaria di Cagliari, Cagliari, Italy Dupilumab is a monoclonal antibody targeting ...

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Bullous Pemphigoid. According to GlobalData, Phase III drugs for Bullous Pemphigoid does not have ...

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase II drugs for Systemic Sclerosis ...